GlassScriptPhysician profile
Brian Campbell Jimenez
NPI 1548668916
$7,102.07
in general payments reported to CMS, 2019-2025
53 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $145 · 2021: $997 · 2022: $1,470 · 2023: $1,374 · 2024: $1,482 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421 · Education: $67.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.46 |
| Education | $67.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $947.45 | 2021-2025 | |
| Pfizer INC. | $448.20 | 2021-2025 | |
| Emd Serono, INC. | $361.49 | 2021-2025 | Bavencio |
| Lilly USA, LLC | $350.00 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $278.34 | 2020-2023 | Opdivo |
| Janssen Biotech, INC. | $245.73 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Ipsen Biopharmaceuticals, INC | $235.62 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Celgene Corporation | $230.43 | 2020-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $229.68 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $228.63 | 2021-2023 | Adcetris |
| Genzyme Corporation | $202.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $188.13 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $173.46 | 2021-2025 | Tecentriq, Lunsumio, Phesgo |
| Daiichi Sankyo INC. | $166.75 | 2021-2025 | Enhertu |
| Eisai INC. | $154.89 | 2021-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.25 | 2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $152.20 | 2021-2025 | Keytruda |
| Beigene USA, INC. | $147.78 | 2021-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $145.01 | 2021-2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $135.91 | 2023-2025 | Venclexta |
| Astellas Pharma US INC | $122.47 | 2023-2025 | Xospata, Vyloy, Padcev |
| Gilead Sciences, INC. | $121.91 | 2023-2025 | Trodelvy |
| Array Biopharma INC | $114.67 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $114.01 | 2024-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.77 | 2021-2023 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $107.06 | 2021-2023 | Imbruvica, Epkinly |
| Puma Biotechnology, INC. | $96.56 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.08 | 2023-2025 | Ninlaro, Fruzaqla |
| Blueprint Medicines Corporation | $93.07 | 2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $86.33 | 2023-2025 | Fotivda |
| Sobi, INC | $85.01 | 2022-2023 | |
| Incyte Corporation | $83.05 | 2021-2025 | Jakafi, Monjuvi |
| Pharmaessentia USA Corporation | $65.78 | 2023-2025 | Besremi |
| Exelixis INC. | $62.00 | 2023-2025 | Cabometyx |
| Genentech, INC. | $49.95 | 2021 | |
| Karyopharm Therapeutics INC. | $46.19 | 2021-2023 | Xpovio |
| Adaptive Biotechnologies Corporation | $45.44 | 2023-2024 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Recordati_rare_diseases_inc. | $39.73 | 2024-2025 | Sylvant |
| Azurity Pharmaceuticals, INC. | $36.71 | 2025 | Danziten, Vivimusta |
| Kite Pharma, INC. | $35.36 | 2022-2023 | Yescarta |
| Mirati Therapeutics, INC. | $35.23 | 2023-2024 | Krazati |
| G1 Therapeutics, INC. | $30.61 | 2022 | |
| Beone Medicines USA, INC. | $29.74 | 2025 | Brukinsa |
| Emmaus Medical, INC. | $29.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.15 | 2021-2023 | |
| Geron Corporation | $20.43 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $19.29 | 2024 | Provenge |
| Tersera Therapeutics LLC | $17.18 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.38 | 2023 | Yonsa, Odomzo |
| Taiho Oncology, INC. | $14.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.49 | 2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $14.44 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Campbell Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.